The Biotherapies and Bioproduction of Innovative Therapies (BBTI) Research Program (PEPR), launched by the French government in 2021, is one of the major initiatives in the Biotherapies and Bioproduction of Innovative Therapies acceleration strategy of the France 2030 plan.

This research program, whose scientific management has been entrusted to Inserm and CEA, aims to contribute to the development of tomorrow’s biotherapies and associated key technologies.

It also aims to federate the national academic research ecosystem and promotes close links with industry and hospitals.
The PEPR is part of a wider drive to consolidate France’s leadership and competitiveness in this sector research and manufacturing processes.

Latest news

PEPR Biotherapies’ first call for projects

Opening : 15 april 2024 – Deadline : 5 september 2024

PhD candidate in pharmacology and immunology

The RNAvac project is looking for a PhD student. The thesis topic will be centered around the “Comprehensive analysis of immune responses to mRNA-based vaccines”



ACCelerating Research for Early Development of Innovative Antibodies


Multidisciplinary approach to stimulate the bioproduction and engineering of Gram+ bacteria’s Extracellular Vesicles (EVs) for therapeutic applications to treat inflammation

Bioengineered Skin-France

Bioengineering of next-generation skin substitutes for cutaneous regeneration


Improving the whole chain of large scale AAV bioproduction through disruptive technologies


Development of biotherapies based on the local delivery of therapeutic RNAs by hybrid functionalized extracellular vesicles (EVs) for musculoskeletal regeneration


Development of breakthrough technologies in gene editing


Generation of iChondrocytes to regenerate articular cartilage

iPSC France

Genomic editing of stable universal pluripotent stem cells for allogeneic cell biotherapies


Innovative approaches for quality control to support the industrial deployment of future gene therapy products.


New generation of mRNA-based vaccines


From engineering of iPS-derived mesenchymal stromal cell-derived extracellular vesicles to clinical translation


B-cell genetic engineering for new therapeutic and vaccine modalities